Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
830,3 EUR | -4,80% |
|
-5,09% | +56,40% |
08:13 | Roche meldt positieve eerste resultaten in CT-966 medicijnstudie tegen zwaarlijvigheid | RE |
16/07 | Aclaris Therapeutics verkoopt Olumiant royalty's, mijlpaalbetalingen van Eli Lilly | MT |
Vakgebied
- endocrinologie (57,7%): producten voor de behandeling van osteoporose, diabetes en groeiproblemen;
- oncologie (19,5%);
- immunologische ziekten (11,1%);
- neurologie (8,4%): voornamelijk geneesmiddelen voor de behandeling van depressie en schizofrenie;
- overige (3,3%).
De netto-omzet is als volgt geografisch verdeeld: Verenigde Staten (63,9%), Europa (18,1%), Japan (4,9%), China (4,5%) en overige (8,6%).
Aantal werknemers: 43 000
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80% |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62% |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30% |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28% |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01-01-96 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-23 |
Alonzo Weems
CMP | Compliance Officer | - | 01-01-97 |
Chief Tech/Sci/R&D Officer | 50 | 01-01-18 | |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17-05-21 |
Johna Norton
PRN | Corporate Officer/Principal | 57 | 01-04-17 |
Corporate Officer/Principal | - | 01-01-05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
- | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 25-01-21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01-04-09 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 01-01-05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01-02-16 |
William Kaelin
BRD | Director/Board Member | 66 | 04-06-12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01-01-96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01-10-16 |
Director/Board Member | 52 | 12-12-11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01-09-13 |
Karen Walker
BRD | Director/Board Member | 62 | 01-12-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 950 770 386 | 948 833 114 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 86 356 634 $ |
8 084 411 | 6.83% | 40 989 257 $ | |
4 000 000 | 7.23% | 23 000 000 $ | |
PROQR THERAPEUTICS N.V. 16.37% | 13 371 562 | 16.37% | 22 196 793 $ |
AC IMMUNE SA 3.64% | 3 615 328 | 3.64% | 14 425 159 $ |
21 776 804 | 7.60% | 10 654 955 $ | |
2 500 000 | 7.07% | 8 811 050 $ | |
125 405 | 1.81% | 1 220 191 $ |
Bedrijfsgegevens
![Adres Eli Lilly and Company(LLY)](https://cdn.zonebourse.com/static/address/437930.png)
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Eli Lilly SA
![]() Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Kinsale Financial Services
| |
ELI Lilly & Company (India) Pvt Ltd.
![]() ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Lilly Ventures Fund I LLC
![]() Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Export SA (Switzerland)
![]() Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Eli Lilly Group Pension Trustees Ltd.
![]() Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The company is based in Basingstroke, UK. |
Financial Conglomerates
|
Eli Lilly (Suisse) SA
| |
Eli Lilly Vostok SA
| |
Eli Lilly Services India Pvt Ltd.
![]() Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,47% | 627 mld. | |
-3,66% | 363 mld. | |
+15,06% | 318 mld. | |
+9,18% | 299 mld. | |
+12,68% | 234 mld. | |
+16,37% | 225 mld. | |
+15,67% | 179 mld. | |
+2,47% | 167 mld. | |
+1,62% | 125 mld. |